Nivalis Therapeutics, Inc. (NVLS) Files Form 4 Insider Buying : Jon Congleton Buys 5,000 Shares

Nivalis Therapeutics, Inc. (NVLS): Jon Congleton , CEO of Nivalis Therapeutics, Inc. purchased 5,000 shares on Jun 16, 2016. The Insider buying transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.87 per share for a total value of $19,344.50 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 23, 2016, Jon Congleton (CEO) purchased 5,000 shares at $4.38 per share price.On Dec 11, 2015, Robert E Conway (director) purchased 10,000 shares at $8.10 per share price.Also, On Jun 24, 2015, Springs Capital Managemen Rock (10% owner) purchased 200,000 shares at $14.00 per share price.On Jun 23, 2015, Bay Master Investors (c Hawkes (10% owner) purchased 17,200 shares at $14.71 per share price.

Shares of Nivalis Therapeutics Inc (NVLS) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -2.42% at $4.03 with 4,79,842 shares getting traded. Post opening the session at $4.06, the shares hit an intraday low of $3.8101 and an intraday high of $4.16 and the price vacillated in this range throughout the day. The company has a market cap of $62 M and the number of outstanding shares has been calculated to be 1,54,62,030 shares. The 52-week high of Nivalis Therapeutics Inc is $20.43 and the 52-week low is $3.68.

Nivalis Therapeutics Inc Money Flow Index Chart

Nivalis Therapeutics Inc. is a United States-based clinical-stage pharmaceutical company. It is engaged in the discovery development and commercialization of product candidates for patients with cystic fibrosis. The Company has developed a portfolio of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) which is used to increase and prolong cystic fibrosis transmembrane conductance regulator (CFTR) activity and to decrease inflammation. Its drug candidate portfolio consists of various compounds for oral intravenous (IV) or inhaled administration. The Company’s lead clinical candidate is N91115 which is an investigational small molecule that addresses a defect in CFTR resulting from mutations in the CFTR gene. N91115 is designed to stabilize CFTR inside the cell and at the cell surface. N91115 is a CFTR stabilizer that modulates CFTR activity.

Leave a Reply

Nivalis Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nivalis Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.